these slides are great. Thanks for sharing.
Good to see that the FDA is looking to expedite approval of products that are successful in EFS - can't wait until the data is released.
Sounds like breakthrough devices need to be providing a treatment that doesnt have any alternatives. Not sure how broadly this can be interpreted...given Edwards already has products in this space, does that mean that breakthrough designation is unlikely for anteris?
Valuation and Timelines, page-14
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $214.5M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $205.8K | 20.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 154 | $10.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.13 | 234 | 2 |
View Market Depth
| Last trade - 12.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |